MDxHealth, a commercial-stage precision diagnostics company, has received a boost in its stock price target from Lake Street Capital. In a research report released on Thursday, Lake Street Capital increased its target from $7.00 to $9.00, maintaining a buy rating on the stock. This adjustment reflects positive sentiment among analysts regarding the company’s prospects and performance.
Several research firms have recently weighed in on MDxHealth’s stock. Craig Hallum initiated coverage on July 17, 2025, assigning a buy rating and a target price of $8.00. Meanwhile, Wall Street Zen upgraded the stock to a hold rating on August 30, 2025. In a separate report, BTIG Research raised its price target from $6.00 to $7.00, also issuing a buy rating. Conversely, Weiss Ratings maintained a sell rating on October 8, 2025. Overall, four analysts have rated MDxHealth as a buy, while one has issued a sell rating. According to data from MarketBeat.com, the stock currently holds an average rating of “Moderate Buy” with an average target price of $7.75.
Recent Earnings Report and Financial Performance
MDxHealth reported its latest earnings results on November 12, 2025. The company posted earnings of ($0.16) per share, falling short of analysts’ expectations of ($0.12) by $0.04. However, the company generated revenue of $27.43 million for the quarter, surpassing the consensus estimate of $24.11 million. Despite these figures, MDxHealth continues to face challenges, with a negative net margin of 34.98% and a negative return on equity of 374.98%. Analysts anticipate that MDxHealth will report an earnings per share of (1.15) for the current fiscal year.
Investment Activity and Analyst Sentiment
Recent changes in investment holdings reflect growing interest in MDxHealth. Perkins Capital Management Inc. increased its stake by 20.1% in the first quarter, now holding 1,181,475 shares valued at approximately $1.68 million. Delta Investment Management LLC significantly boosted its holdings by 459.1%, acquiring an additional 156,100 shares, bringing its total to 190,100 shares valued at around $270,000. AWM Investment Company Inc. also increased its position by 10.6%, now owning 5,221,282 shares worth approximately $7.41 million.
In addition, FreeGulliver LLC and Calamos Advisors LLC entered new stakes in MDxHealth during the second and third quarters, respectively, valued at around $273,000 and $305,000. These movements suggest a growing confidence among institutional investors in MDxHealth’s potential.
MDxHealth operates in the urologic solutions sector, offering innovative testing solutions such as Select mdx, Confirm mdx, and Resolved mdx. These products aim to enhance diagnostic accuracy and patient care for conditions like prostate cancer and urinary tract infections.
As analysts continue to evaluate MDxHealth’s performance and market position, the company’s ability to navigate its challenges while capitalizing on growth opportunities remains crucial for its stakeholders.
